About Segtnan AI

This startup integrates artificial intelligence into healthcare operations to lower costs and enhance patient outcomes through data-driven decision-making. By applying insights from PhD research, the company optimizes resource allocation in medical facilities, improving efficiency and care delivery.

```xml <problem> Detecting and diagnosing brain diseases like Alzheimer's and dementia early is challenging due to limited options and the lack of built-in software in existing PET/MR/CT scanners to comprehensively analyze brain biology and identify Network Diaschisis. This results in delayed diagnoses and fewer opportunities to slow disease progression. </problem> <solution> Segtnan AI offers a globally accessible, AI-powered system that analyzes FDG-PET scans to provide a comprehensive assessment of brain functionality. The system integrates risk assessment for various biological brain diseases and learns from each analyzed image. The AI maps the brain's biology in 3D, providing a "Brain Score" biomarker that quantifies overall brain functionality and aids in identifying Network Diaschisis. This serverless online platform can be integrated into any hospital's existing infrastructure to enhance diagnostic accuracy and support clinical decision-making. </solution> <features> - AI-powered analysis of FDG-PET scans, mapping the brain's biology in 3D - Segtnan Brain Score: a biomarker quantifying overall brain functionality - Identification of Network Diaschisis - Serverless online platform for seamless integration with existing hospital systems - AI model that learns and improves with each analyzed image - Validated on data from thousands of patients, demonstrating high sensitivity and specificity </features> <target_audience> The primary target audience includes hospitals, research institutions, and healthcare providers seeking to improve the early detection and diagnosis of neurological disorders using advanced brain scan analysis. </target_audience> ```

What does Segtnan AI do?

Where is Segtnan AI located?

Segtnan AI is based in Odense, Denmark.

When was Segtnan AI founded?

Segtnan AI was founded in 2018.

Location

Odense, Denmark

Founded

2018

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Segtnan AI

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

segtnan.ai 500+

Founded 2018 – Odense, Denmark

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Detecting and diagnosing brain diseases like Alzheimer's and dementia early is challenging due to limited options and the lack of built-in software in existing PET/MR/CT scanners to comprehensively analyze brain biology and identify Network Diaschisis. This results in delayed diagnoses and fewer opportunities to slow disease progression.

Solution

Segtnan AI offers a globally accessible, AI-powered system that analyzes FDG-PET scans to provide a comprehensive assessment of brain functionality. The system integrates risk assessment for various biological brain diseases and learns from each analyzed image. The AI maps the brain's biology in 3D, providing a "Brain Score" biomarker that quantifies overall brain functionality and aids in identifying Network Diaschisis. This serverless online platform can be integrated into any hospital's existing infrastructure to enhance diagnostic accuracy and support clinical decision-making.

Features

AI-powered analysis of FDG-PET scans, mapping the brain's biology in 3D

Segtnan Brain Score: a biomarker quantifying overall brain functionality

Identification of Network Diaschisis

Serverless online platform for seamless integration with existing hospital systems

AI model that learns and improves with each analyzed image

Validated on data from thousands of patients, demonstrating high sensitivity and specificity

Target Audience

The primary target audience includes hospitals, research institutions, and healthcare providers seeking to improve the early detection and diagnosis of neurological disorders using advanced brain scan analysis.